Journal article
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: A WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
RJ Commons, JA Simpson, K Thriemer, CS Chu, NM Douglas, T Abreha, SG Alemu, A Añez, NM Anstey, A Aseffa, A Assefa, GR Awab, JK Baird, BE Barber, I Borghini-Fuhrer, U D'Alessandro, P Dahal, A Daher, PJ De Vries, A Erhart Show all
BMC Medicine | BMC | Published : 2019
Abstract
Background: Malaria causes a reduction in haemoglobin that is compounded by primaquine, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The aim of this study was to determine the relative contributions to red cell loss of malaria and primaquine in patients with uncomplicated Plasmodium vivax. Methods: A systematic review identified P. vivax efficacy studies of chloroquine with or without primaquine published between January 2000 and March 2017. Individual patient data were pooled using standardised methodology, and the haematological response versus time was quantified using a multivariable linear mixed effects model with non-linear terms for time. Mean dif..
View full abstractRelated Projects (2)
Grants
Awarded by United States Agency for International Development
Funding Acknowledgements
RJC is supported by a Postgraduate Australian National Health and Medical Research Council (NHMRC) Scholarship and a RACP NHMRC Kincaid-Smith Scholarship. RNP is a Wellcome Trust Senior Fellow in Clinical Science (200909). JAS is funded by an Australian NHMRC Senior Research Fellowship 1104975. KT is funded by the Bill and Melinda Gates Foundation (OPP1164105 and OPP1054404). MVGL and WMM are research fellows supported by the Brazilian Council for Scientific and Technological Development (CNPq). NJW is a Wellcome Trust Principal Fellow. NMA is funded by an Australian NHMRC Senior Principal Research Fellowship (1135820). MJG is supported by an NHMRC Early Career Fellowship (1138860). PD is funded by Tropical Network Fund, Nuffield Department of Clinical Medicine, University of Oxford. WWARN is funded by Bill and Melinda Gates Foundation and Exxon Mobil Foundation grants. This work was supported by the Australian Centre for Research Excellence on Malaria Elimination (ACREME), funded by the NHMRC of Australia (1134989). The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing of the paper. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.